A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: A Gynecologic Oncology Group study

► Gefitinib was evaluated in a phase II trial of advanced endometrial cancer. ► One patient achieved a complete response, though gefitinib did not demonstrate significant clinical activity overall. ► The levels of a soluble truncated form of EGFR, sEGFR, positively correlated with overall survival.